Mar 31, 2021

Jaguar Health Q1 2021 Earnings Report

Reported consolidated financial results for the first quarter of 2021, with Mytesi gross sales and net sales increasing.

Key Takeaways

Jaguar Health reported its first quarter 2021 financial results, highlighting a 250% increase in Mytesi gross sales and a 43% increase in net sales.

Mytesi gross sales were approximately $4.6 million, a 250% increase.

Mytesi net sales were approximately $1.2 million, a 43% increase.

The company hosted an investor webcast on May 17, 2021, to discuss the first quarter 2021 financials and business updates.

Jaguar Health is focused on developing novel, plant-based, non-opioid prescription medicines.

Total Revenue
$1.24M
Previous year: $869K
+42.8%
EPS
-$20.3
Previous year: -$126
-83.9%
Gross Profit
$658K
Cash and Equivalents
$32.3M
Total Assets
$68.7M

Jaguar Health

Jaguar Health

Jaguar Health Revenue by Segment